Luye Selects AstraZeneca to Market its Anti-Cholesterol Drug in China
January 16, 2019 at 05:58 AM EST
Luye Pharma out-licensed mainland China marketing rights for its anti-cholesterol Xuezhikang capsules to AstraZeneca China . Xuezhikang is a fermented form of red yeast rice that is similar to a statin. It has successfully completed US Phase II trials, and the two companies are considering expanding distribution to the US , Europe and emerging markets. They expect Xuezhikang revenues will continue growing at a double-digit rate. The partnership is the first time a China biopharma has partnered China product rights with a multinational company for a product it developed. More details.... Stock Symbols: (HK_8126) (NYSE: AZN) Share this with colleagues: // //
